$EVO

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Evotec SE (Nasdaq: EVO) said it has started an R&D collaboration with Odyssey Therapeutics (Nasdaq: ODTX) to use Evotec’s data-driven discovery platform, screening and compound libraries to identify and validate small-molecule candidates for autoimmune and inflammatory diseases across multiple targets.

Evotec SE (EVO) said it will collaborate with Odyssey Therapeutics (ODTX) on AI-enabled small-molecule discovery for autoimmune and inflammatory diseases. Odyssey will use Evotec’s AI platform, screening tools, and compound libraries to identify and validate drug candidates across multiple targets. Evotec may receive milestone payments, terms undisclosed. ODTX shares closed at $20.89, up 4.66%.

Evotec SE (NASDAQ: EVO) said it entered an R&D collaboration with Odyssey Therapeutics (NASDAQ: ODTX) to use Evotec’s AI-enabled discovery platform and screening capabilities to discover and validate small-molecule drug candidates for autoimmune and inflammatory diseases. Evotec will deliver validated hit series across multiple targets and may receive milestone payments; no financial terms were disclosed.

Evolution AB (publ) said it bought 207,007 of its own shares on 3 Aug 2026, pushing its treasury shareholding above the 5% notification threshold. The company now holds 9,985,643 own shares, or 5.01% of 199,226,613 shares and votes. The buyback is part of a program for up to 19,922,661 shares and EUR 2 billion announced 18 May 2026.

Navan (NASDAQ: NAVN) said Evotec (NASDAQ: EVO; Frankfurt: EVT) selected Navan to run its global travel and expense program across Germany, the UK, U.S., Italy, and France. Evotec aims to unify tools, reduce manual expense entry, and automate reconciliation from card swipes, according to the companies.

Evotec SE (EVO) Q2 2026 earnings call Q&A covered revenue declines and strategy. Management said the BMS collaboration remains healthy and should return to growth in 2027 after a 2026 transition, with JEB growth continuing excluding Sandoz and DOW. D&PD orders rose 28% from a low base, and revised guidance relies mainly on existing contracts.

Evotec said unfavorable FX will cut first-half revenue by about €13 million. It guided Q2 adjusted group EBITDA to about -€20.8 million and -€42.7 million for 1H 2026. Full-year 2026 revenue is now ~€570m-€610m (inc. FX) and adjusted EBITDA -€70m to -€105m. Liquidity rose to €465.6m.

Evotec SE (NASDAQ: EVO) reported preliminary, unaudited Q2 and first-half 2026 results and updated its full-year outlook. It expects H1 2026 revenue of about €300.1m and adjusted EBITDA of about -€42.7m, with liquidity around €465.6m as of June 30. Full-year 2026 revenue guidance is €570-610m and adjusted EBITDA -€70 to -105m, down from prior €700-780m and €0-40m.

Evotec SE (EVO) launched J.TRAIN, a turnkey continuous biopharmaceutical manufacturing solution for partners to install on-site. It combines modular cleanrooms, cGMP-compliant automation, and digital validation, aiming for capacity setup in as little as 18 months. Evotec cited a December 2025 Sandoz deal and said J.TRAIN was unveiled in April 2026. EVO stock last close: $2.80 (+2.19%).